54325 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 07
00:32 UTC
|
MD
Pediatrix Medical Group
|
◎ Target | A.J. Rice ★★★★☆ #448 | Neutral | $25.00→ $28.00+12.0% |
|
Aug 07
00:32 UTC
|
MCK
McKesson
|
◎ Target | Charles Rhyee ★★★★☆ #421 | Buy | $989.00→ $1,006.00+1.7% |
|
Aug 07
00:32 UTC
|
MCK
McKesson
|
◎ Target | Kevin Caliendo ★★★★☆ #545 | Buy | $1,050.00→ $1,080.00+2.9% |
|
Aug 07
00:32 UTC
|
LPX
Louisiana-Pacific
|
◎ Target | Michael Roxland ★★★☆☆ #1205 | Buy | $91.00→ $89.00-2.2% |
|
Aug 07
00:32 UTC
|
LPX
Louisiana-Pacific
|
◎ Target | Matthew Bouley ★★★☆☆ #1427 | Overweight | $93.00→ $92.00-1.1% |
|
Aug 07
00:32 UTC
|
LPX
Louisiana-Pacific
|
◎ Target | Susan Maklari ★★★★☆ #930 | Sell | $66.00→ $74.00+12.1% |
|
Aug 07
00:32 UTC
|
LLY
Eli Lilly and Company
|
◎ Target | Carter Gould ★★★★★ #236 | Overweight | $1,350.00→ $1,410.00+4.4% |
|
Aug 07
00:32 UTC
|
LLY
Eli Lilly and Company
|
◎ Target | Mohit Bansal ★★★☆☆ #1220 | Overweight | $1,280.00→ $1,330.00+3.9% |
|
Aug 07
00:32 UTC
|
LGND
Ligand Pharmaceuticals
|
◎ Target | Joseph Pantginis ★★☆☆☆ #2831 | Buy | $289.00→ $358.00+23.9% |
|
Aug 07
00:32 UTC
|
LGEN
Legal & General Group
|
◎ Target | firm only | Buy | GBX 353→ GBX 385+9.1% |
|
Aug 07
00:32 UTC
|
LFMD
LifeMD
|
◎ Target | William Woods not yet tracked | Buy | $10.00→ $8.00-20.0% |
|
Aug 07
00:32 UTC
|
LFMD
LifeMD
|
◎ Target | David Larsen ★★★★☆ #561 | Buy | $10.00→ $9.00-10.0% |
|
Aug 07
00:32 UTC
|
LEN
Lennar
|
◎ Target | Jonathan Bettenhausen ★★★☆☆ #1874 | Hold | $90.00→ $80.00-11.1% |
|
Aug 07
00:32 UTC
|
LCII
LCI Industries
|
◎ Target | Nathan Jones ★★★☆☆ #1682 | Buy | $137.00→ $130.00-5.1% |
|
Aug 07
00:32 UTC
|
KYMR
Kymera Therapeutics
|
◎ Target | Eliana Merle ★★★☆☆ #1386 | Overweight | $133.00→ $139.00+4.5% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Nick Altmann ★★★★★ #320 | Buy | $30.00→ $25.00-16.7% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Billy Fitzsimmons ★★★★★ #204 | Overweight | $26.00→ $23.00-11.5% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Parker Lane not yet tracked | Buy | $24.00→ $22.00-8.3% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Brett Huff ★★★☆☆ #2053 | Overweight | $24.00→ $25.00+4.2% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Jackson Ader ★★★★☆ #972 | Overweight | $35.00→ $29.00-17.1% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Ryan MacWilliams ★★★★★ #303 | Overweight | $26.00→ $22.00-15.4% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Terry Tillman ★★★★★ #297 | Buy | $35.00→ $30.00-14.3% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | David Hynes ★★★★★ #300 | Buy | $32.00→ $29.00-9.4% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Derrick Wood ★★★★☆ #447 | Buy | $27.00→ $26.00-3.7% |
|
Aug 07
00:32 UTC
|
KVYO
Klaviyo
|
◎ Target | Raimo Lenschow ★★★★☆ #661 | Overweight | $25.00→ $22.00-12.0% |
|
Aug 07
00:32 UTC
|
KTOS
Kratos Defense & Security Solutions
|
◎ Target | Jonathan Siegmann not yet tracked | Buy | $134.00→ $115.00-14.2% |
|
Aug 07
00:32 UTC
|
KLIC
Kulicke and Soffa Industries
|
◎ Target | Charles Shi ★☆☆☆☆ #3079 | Buy | $105.00→ $115.00+9.5% |
|
Aug 07
00:32 UTC
|
KHC
Kraft Heinz
|
◎ Target | Peter Grom ★★★★★ #270 | Neutral | $25.00→ $27.00+8.0% |
|
Aug 07
00:32 UTC
|
KHC
Kraft Heinz
|
◎ Target | Robert Moskow ★★★★☆ #388 | Hold | $20.00→ $22.00+10.0% |
|
Aug 07
00:32 UTC
|
KHC
Kraft Heinz
|
◎ Target | Michael Lavery ★★★☆☆ #1017 | Neutral | $24.00→ $25.00+4.2% |
|
Aug 07
00:32 UTC
|
KBL
K-Bro Linen
|
◎ Target | firm only | Buy | C$52.00→ C$54.00+3.8% |
|
Aug 07
00:32 UTC
|
KBL
K-Bro Linen
|
◎ Target | firm only | Outperform | C$50.00→ C$54.00+8.0% |
|
Aug 07
00:32 UTC
|
KBL
K-Bro Linen
|
◎ Target | firm only | Outperform | C$50.00→ C$55.00+10.0% |
|
Aug 07
00:32 UTC
|
KAI
Kadant
|
◎ Target | Kurt Yinger ★★☆☆☆ #2336 | Neutral | $306.00→ $335.00+9.5% |
|
Aug 07
00:32 UTC
|
JOBY
Joby Aviation
|
◎ Target | Chris Pierce ★☆☆☆☆ #3145 | Buy | $18.00→ $15.00-16.7% |
|
Aug 07
00:32 UTC
|
JNJ
Johnson & Johnson
|
◎ Target | Vamil Divan ★★★★☆ #905 | Buy | $270.00→ $287.00+6.3% |
|
Aug 07
00:32 UTC
|
JAN
JAN
|
◎ Target | Richard Anderson ★★★☆☆ #1553 | Overweight | $30.00→ $34.00+13.3% |
|
Aug 07
00:32 UTC
|
IRON
Disc Medicine
|
◎ Target | Douglas Tsao ★★★☆☆ #1638 | Buy | $118.00→ $120.00+1.7% |
|
Aug 07
00:32 UTC
|
IRM
Iron Mountain
|
◎ Target | Eric Luebchow ★★☆☆☆ #2766 | Overweight | $135.00→ $140.00+3.7% |
|
Aug 07
00:32 UTC
|
IFF
International Flavors & Fragrances
|
◎ Target | Ben Klieve ★☆☆☆☆ #3142 | Buy | $100.00→ $105.00+5.0% |
|
Aug 07
00:32 UTC
|
IFF
International Flavors & Fragrances
|
◎ Target | Joshua Spector ★★★☆☆ #1727 | Neutral | $84.00→ $91.00+8.3% |
|
Aug 07
00:32 UTC
|
IEX
IDEX
|
◎ Target | Matt Summerville ★★☆☆☆ #2424 | Neutral | $230.00→ $240.00+4.3% |
|
Aug 07
00:32 UTC
|
IEX
IDEX
|
◎ Target | John Eade ★★★★☆ #865 | Buy | $250.00→ $260.00+4.0% |
|
Aug 07
00:32 UTC
|
IAG
iA Financial
|
◎ Target | firm only | C$208.00→ C$220.00+5.8% | |
|
Aug 07
00:32 UTC
|
IAG
iA Financial
|
◎ Target | firm only | Hold | C$205.00→ C$220.00+7.3% |
|
Aug 07
00:32 UTC
|
IAG
iA Financial
|
◎ Target | firm only | Sec→ r Perform | C$198.52→ C$223.00+12.3% |
|
Aug 07
00:32 UTC
|
IAG
iA Financial
|
◎ Target | firm only | Outperform | C$215.00→ C$225.00+4.7% |
|
Aug 07
00:32 UTC
|
IAG
iA Financial
|
◎ Target | firm only | Sec→ r Perform | C$167.00→ C$213.00+27.5% |
|
Aug 07
00:32 UTC
|
HUT
Hut 8
|
◎ Target | Patrick Moley ★★★☆☆ #1855 | Overweight | $127.00→ $143.00+12.6% |
|
Aug 07
00:32 UTC
|
HUT
Hut 8
|
◎ Target | Bill Papanastasiou ★☆☆☆☆ #3077 | Outperform | $157.00→ $154.00-1.9% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.